Home › Funds › D. E. Shaw & Co › BBIO
D. E. Shaw & Co position in BBIO
BRIDGEBIO PHARMA INC · Health Care
Latest position (Q2 2026)3.66M sh
Reported value held$272.89M
Portfolio Weight0.14%
First reportedQ3 2021
Last changeReduce
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2021 | 166.59K | $7.81M | New |
| Q4 2021 | 1.29M | $21.45M | Add |
| Q1 2022 | 2.47M | $1.19M | Add |
| Q2 2022 | 2.45M | $22.23M | Reduce |
| Q3 2022 | 2.36M | $23.44M | Reduce |
| Q4 2022 | 2.70M | $20.58M | Add |
| Q1 2023 | 12.00M | $8.85M | Add |
| Q2 2023 | 27.00M | $21.09M | Add |
| Q3 2023 | 21.32M | $20.47M | Reduce |
| Q4 2023 | 21.32M | $25.66M | Hold |
| Q1 2024 | 417.89K | $12.92M | Reduce |
| Q2 2024 | 224.13K | $5.68M | Reduce |
| Q3 2024 | 80.75K | $2.06M | Reduce |
| Q4 2024 | 51.75M | $44.14M | Add |
| Q1 2025 | 83.15K | $2.87M | Reduce |
| Q2 2025 | 22.06M | $20.66M | Add |
| Q3 2025 | 28.65M | $28.35M | Add |
| Q4 2025 | 2.21M | $169.35M | Reduce |
| Q1 2026 | 62.78M | $106.54M | Add |
| Q2 2026 | 3.66M | $272.89M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding BBIO
- Vanguard Group 16.86M sh · $1.29B · Q4 2025
- Janus Henderson Group 13.18M sh · $978.61M · Q1 2026
- Farallon Capital Management 10.74M sh · $800.14M · Q2 2026
- Viking Global Investors 9.95M sh · $741.02M · Q2 2026
- Two Sigma Investments 4.75M sh · $353.43M · Q2 2026
- Geode Capital Management 3.42M sh · $254.67M · Q2 2026
- Manulife Financial 1.96M sh · $145.66M · Q2 2026
- Charles Schwab Investment Management 1.71M sh · $127.32M · Q2 2026
- Norges Bank Investment Management 1.69M sh · $126.15M · Q2 2026
- Morgan Stanley 1.69M sh · $126.14M · Q2 2026
- Point72 Asset Management 1.53M sh · $114.16M · Q2 2026